AMNEAL PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $42.00K, a 93.87% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $38.00K, a 44.93% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $553.00K, a 266.23% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $653.00K, a 5.83% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.96M, a 69.84% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.15M, a 155.88% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $451.00K, a 31.87% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $662.00K, a 22.39% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $42.00K 10-Q · filed 2026-08-06 | $1.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $38.00K 10-Q · filed 2026-05-07 | $1.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $553.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.96M 10-K · filed 2026-02-27 |
| 2025-09-30 | $653.00K 10-Q · filed 2025-11-06 | $1.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $685.00K 10-Q · filed 2026-08-06 | $1.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $69.00K 10-Q · filed 2026-05-07 | $1.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.15M 10-K · filed 2026-02-27 |
| 2024-09-30 | $617.00K 10-Q · filed 2025-11-06 | $1.05M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $358.00K 10-Q · filed 2025-08-07 | $837.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $28.00K 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $451.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | $408.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $662.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $423.00K 10-Q · filed 2023-11-09 | $681.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $128.00K 10-Q · filed 2023-08-08 | $411.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $111.00K 10-Q · filed 2023-05-09 | $288.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $853.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $153.00K 10-Q · filed 2022-11-07 | $939.00K derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $5.00K 10-Q · filed 2022-08-08 | $844.00K derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $676.00K 10-Q · filed 2022-05-06 | $992.00K derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $321.00K 10-K · filed 2023-03-03 |
| 2020-09-30 | $58.00K 10-Q · filed 2021-11-08 | $231.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $153.00K 10-Q · filed 2021-08-09 | $173.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.00K 10-Q · filed 2021-05-07 | $395.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.40M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | |
| 2019-06-30 | $375.00K 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $1.01M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |